Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2011

View Archived Issues

New cDNA library vaccine cures experimental prostate cancer

Plant-produced protein blocks transmission of Plasmodium falciparum

Investigation of thiostrepton uncovers new possible target for breast cancer therapy

Taisho synthesizes new vasopressin V1B receptor antagonists

KalVista receives funding to develop new treatment for diabetic macular edema

Merck & Co. presents novel Lck inhibitors

Spinifex Pharmaceuticals obtains funding to expand phase II EMA-401 program

Novacta Biosystems discloses novel lantibiotic-based agents

Chinese company prepares novel tyrosine-protein kinase inhibitors

Pharmaneuroboost receives IRB approval for phase III PNB-01 trial

Theron Pharmaceuticals patents novel muscarinic acetylcholine M3 receptor antagonists

FDA awards fast track status to Pharmasset's PSI-938

Allergan prepares novel prostanoid EP2 receptor agonists

Phase III study of treprostinil diethanolamine does not meet primary endpoint

Clavis Pharma expands pivotal phase III elacytarabine trial

FDA approves Botox for new indication

RegeneRx completes enrollment in phase II dry eye syndrome study

Pharmaxis resubmits data for E.U. Bronchitol marketing application

FDA issues communication regarding high doses of citalopram

Peregrine reports survival data from bavituximab plus docetaxel breast cancer study

NICE issues recommendation regarding golimumab

SIGA receives NIH grant to develop antiviral drug

Senesco Technologies and Mayo Clinic finalize agreement to study SNS01-T

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...